Skip to main content
. 2022 Jul 22;13:955825. doi: 10.3389/fmicb.2022.955825

Figure 5.

Figure 5

Volcano plot showing the contribution of nVFCs in SF3 and CK3 in OPLS-DA. The first data in the brackets is the number of metabolites, the second data are the percentage of each metabolites in the total nVFCs in CK3 and the third data is that in SF3. 1: Prolyl-Valine; 2:LysoPE(0,0/22,0); 3:Enkephaline, (D-Ala)2-Leu; 4: Agavoside A; 5: 6-{[(16S)-5,7-dihydroxy-8,8,12,16-tetramethyl-3-[1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-10-methylidene-9-oxo-17-oxa-4-azabicyclo[14.1.0]heptadec-4-en-11-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid; 6: Gamma-Glutamylphenylalanine; 7: 6-{[(16S)-5,7-dihydroxy-8,8,10,16-tetramethyl-3-[1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-12-methylidene-9-oxo-17-oxa-4-azabicyclo[14.1.0]heptadec-4-en-11-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid; 8: Asp-Phe; 9: Physagulin D; 10: (+/−)-Hexanoylcarnitine; 11: Isoleucyl-Leucine; 12: Adenosine 3′-monophosphate; 13: PS(MonoMe(11,5)/MonoMe(11,3)); 14: Uridine diphosphate-N-acetylglucosamine; 15: Physapruin B; 16: 7a-Hydroxy-5b-cholanic acid; 17: Isoleucyl-Isoleucine; 18: Isoleucyl-Tyrosine; 19: Digalacturonate; 20: 2,10-Bisaboladiene-1,4-diol; 21: (+/−)-Octanoylcarnitine; 22: Isoleucyl-Alanine; 23: 2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-6-(3-methylbut-2-en-1-yl)-3,4-dihydro-2H-1-benzopyran-4-one; 24: N-(2-Phenylethyl)-acetamide; 25: L-cis-Cyclo(aspartylphenylalanyl); 26: Leucyl-Alanine; 27: Sulfolithocholylglycine; 28: Curcumadiol; 29: Caryoptosidic acid; 30: Ascorbyl stearate; 31: Acetylcholine; 32: 1-Methylhypoxanthine.